Skip to main content
Fig. 4 | Journal of Neuroinflammation

Fig. 4

From: α1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid β1–42-stimulated murine astrocytes

Fig. 4

Treatment with A1AT abrogated Aβ1–42-induced upregulation of NLRP3 mRNA and protein in primary astrocytes. Western blot confirmed an Aβ1–42-induced significant increase of NLRP3 protein levels at 3 h (a) and 6 h (b). Co-treatment with A1AT significantly attenuated this increase at 3 h (a) and 6 h (b) stimulation time. Addition of MCC950 did not alter NLRP3-protein levels in all treatment groups. Treatment with Aβ1–42 significantly increased mRNA levels of NLRP3 in astrocytes at 3 h (c) and 6 h (d). Co-treatment with A1AT significantly blocked this increase in NLRP3 mRNA expression. MCC950-pretreatment had no effects on NLRP3 mRNA expression at 3 h and 6 h. Data of n = 3 in triplicate represent mean ± SD. */ap < 0.05; **/aap < 0.01; ***/aaap < 0.001, ns not significant compared to untreated cell control (ctr)

Back to article page